Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Famitinib and Chemotherapy as Neoadjuvant Treatment for Thoracic Esophageal Squamous Cell Carcinoma
NCT07796113Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, famitinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Started Oct 2025; status: recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07796113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796113.